Fig. 6
Ruxolitinib treatment inhibited the production of proinflammatory cytokines and the expression of STAT1 but promoted the expression of STAT6 in macrophages in vitro. A Levels of IL-6, TNF, and MCP1 production in macrophages isolated from wild-type mice (females/20 weeks) following in vitro treatment with ruxolitinib were determined utilizing CBA and flow cytometry. B The expression of phosphorylated (p-) and unphosphorylated STAT1 and STAT6 in macrophages was assessed by western blotting. C Amounts of STAT1 and STAT6 determined by densitometry of the protein bands from two experiments. β-Actin was the loading control. The symbols R 0 µM, R 1 µM, R 5 µM and R 10 µM correspond to the various concentrations of ruxolitinib at 0 µM, 1 µM, 5 µM and 10 µM, respectively. The data are representative of 2–3 independent experiments with similar results. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
